In May 2023, a novel tracer, flotufolastat F 18 (POSLUMA®), formerly referred to as 18 F-rhPSMA-7.3, was approved by the FDA as a PSMA-PET tracer for the staging of prostate cancer patients with a ...
In November 2023, the United States Food and Drug Administration (FDA) approved enzalutamide, with or without concurrent leuprolide therapy, for conventional imaging-defined non-metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback